Teva- Pharmaceutical Industries Ltd
NYSE: TEVA
$17.50
+$0.07 (+0.4%)
Closing Price on November 7, 2024
TEVA Articles
Analysts at at Merrill Lynch see 2014 as a promising year for biotech mergers and acquisitions. A new research report shows which companies they believe will make acquisitions or which will be...
Published:
Teva Pharmaceutical resume a deal-making strategy that made it one of the most acquisitive drug companies of the past decade. Could one of these biotech takeover candidates be the next target?
Published:
These arethe top analyst upgrades, downgrades and initiations seen from Wall Street research firms for Tuesday, January 7.
Published:
These are the top analyst upgrades, downgrades and initiations seen from Wall Street research firms on Monday, December 30, 2013.
Published:
ThinkstockWith less than a week left in what has been the best year for the S&P 500 since 1997, we have reviewed our top Wall Street firms for their stocks priced under $10 that may have gigantic...
Published:
ThinkstockPfizer Inc.’s (NYSE: PFE) patent protecting popular erectile dysfunction drug Viagra from generic competition may not expire until April 2020, but Teva Pharmaceutical Industries Ltd....
Published:
ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) has moved from a great growth story to one of promise, to one of habitual disappointment. The company’s 2014 guidance is soft yet again....
Published:
ThinkstockThe market for pharmaceuticals and biotech drugs just keeps growing. The so-called patent cliff may be affecting Big Pharma companies locally, but a new report from IMS Health shows that...
Published:
Jon OggThis week marks the beginning of the end for earnings season, and both the Dow Jones Industrial Average and S&P 500 hit new all-time highs last week. Now investors and traders alike are...
Published:
ThinkstockAfter denying rumors earlier this week that its CEO was considering resigning, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced Wednesday morning that President and Chief...
Published:
Jon OggWe are knee-deep in corporate earnings reports and markets are surging to new all-time highs. Investors and traders alike are wondering which stocks to buy and which to sell in the current...
Published:
ThinkstockWith yields on 10-year Treasury bonds up nearly 1.5% since early May and briefly touching 3.0% last week, the impact of higher rates on stocks continues to be top of mind for investors. The...
Published:
Last Updated:
ThinkstockMerck & Co. Inc. (NYSE: MRK) is seeing one more drug drive off the patent cliff. News was released on Monday by Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) that it and Perrigo Co....
Published:
August 5, 2013: U.S. equity markets opened lower this morning, lacking any major news of interest from around the globe. In Europe, eurozone non-manufacturing PMI rose slightly even though German PMI...
Published:
Last Updated:
These are the top analyst upgrades, downgrades and initiations from select Wall Street research calls on Monday, August 5, 2013. They include Chubb, Dow Chemical, Teva Pharmaceutical and Qualcomm.
Published:
Last Updated: